You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Carbon Nanofiber [F-18] Fluoride Ion Concentration for High Speed Biomarker Production

    SBC: NANOTEK, LLC            Topic: 04b

    78954 The DOE has expressed a need for developing tools that can improve and simplify production of radiolabeled compounds. Conventional synthesis of PET radiotracers is hampered by the complex and sensitive synthesis processes that often produce low yields, consume costly precursors, and can take hours to complete. If fluoride ion could be concentrated into microliter volumes of dry solvent qui ...

    STTR Phase I 2005 Department of Energy
  2. Digital Signal Processing Electonics for Silicon Strip Detectors

    SBC: RIS CORP.            Topic: 44a

    78109 Large-area, position-sensitive silicon strip detector arrays are being developed for nuclear physics research. In this application, the traditional electronic processing of the detector signals, along with mixed analog and digital function blocks, largely determines the complexity and cost of such systems. Next generation electronics systems are being constructed using pipelined digital pr ...

    STTR Phase I 2005 Department of Energy
  3. Gene Expression and Diagnosis of Diabetes

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are difficult to diagnose, as the symptoms can be nonspecific. A single test that could readily distinguish between an autoimmune and non-autoimmune disorder would allow physicians to focus efforts on the specific disease that affects the patient. This is critical for diabetes mellitus (DM), which has two subsets, Type I and Type II. The sub ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. High Purity Amphotericin B: A Safer Antimycotic in AIDS

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cumberland Pharmaceuticals and the University of Mississippi Mycotic Research Centers' long-term goal will be to improve anti-fungal pharmacotherapy particularly for patients with human immunodeficiency infections (HIV). We are jointly developing a high purity amphotericin B (AmB HP) product for intravenous administration. The nominal purity of AmB HP is 95%; ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. MRI Quantification of Postinfarct Myocardial Viability

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a novel method for MRI quantification of postinfarct myocardial viability. Ultimately, the commercial embodiment of this method will be a software package that will convert a set of 2D cardiac MRI images to a 3D Myocardial Viability Map (MV) with a voxel-by-voxel resolution. In human clinical use, the package woul ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Optimal Hydrophobicity of Lipoid Gene Delivery Agents

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cationic lipid-like compounds are commonly used in vitro and in vivo to deliver DNA to cells for the purposes of expressing exogenous genes. A number of clinical trials have indicated the promise of these agents for gene therapy, however lipid-based delivery remains less effective than the alternative viral vectors. Nevertheless, vast improvements have been mad ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Realistic Phantom Series for OLINDA/EXM Version 2

    SBC: RADAR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The OLINDA/EXM code, which replaces the popular MIRDOSE code for calculating dose estimates in nuclear medicine applications, was given an exemption by the FDA on June 15, 2004 to be distributed as a medical device. The code will have a 3 year lifetime, and may be considered for re-release in June of 2007. The current code contains the traditional phantom typ ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Utility of a Novel Anthracycline Analog in Psoriasis

    SBC: GEM Pharmaceuticals            Topic: N/A

    DESCRIPTION (provided by applicant): Psoriasis is a common immune-mediated disease that affects approximately 2% of the US and European populations and significantly impacts the quality of life. T cells are recognized as primary mediators of the disease and new generation therapies aimed at eliminating reactive T cells or interfering with the immunologic cascade caused by their activation have bee ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government